LOG IN
SIGN UP
MARKET
MGNX
MGNX
Macrogenics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
3.430
-0.140
-3.92%
After Hours: 3.430 0 0.00% 19:55 05/26 EDT
OPEN
3.560
PREV CLOSE
3.570
HIGH
3.630
LOW
3.420
VOLUME
492.50K
TURNOVER
0
52 WEEK HIGH
32.81
52 WEEK LOW
3.420
MARKET CAP
210.37M
P/E (TTM)
-0.9636
1D
5D
1M
3M
1Y
5Y
BRIEF-Macrogenics Announces Appointment Of William Heiden To Board Of Directors
reuters.com · 3d ago
MacroGenics Announces Appointment of William Heiden to Board of Directors
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of W...
GlobeNewswire · 3d ago
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's m...
GlobeNewswire · 05/17 20:01
6 Analysts Have This to Say About Macrogenics
Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter:
Benzinga · 05/04 18:05
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday.
Benzinga · 05/04 17:45
Bright Health, TransMedics top healthcare gainers; Connect Biopharma, Amarin lead losers' pack
Gainers: Bright Health Group (BHG) +21%. TransMedics Group (TMDX) +21%. Belite Bio (BLTE) +11%. Sharps Technology (STSS) +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma (CNTB) -45%. Amarin (AMRN) -43%. Kezar Life Sciences (KZR) -35%. MacroGenics (MGNX)...
Seekingalpha · 05/04 14:04
--SVB Leerink Adjusts MacroGenics' Price Target to $15 from $23, Keeps Outperform Rating
MT Newswires · 05/04 09:56
--Guggenheim Downgrades MacroGenics to Neutral From Buy
MT Newswires · 05/04 09:47
No Data
Learn about the latest financial forecast of MGNX. Analyze the recent business situations of Macrogenics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 12 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
33.33%Strong Buy
58.33%Buy
8.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MGNX stock price target is 28.33 with a high estimate of 50.00 and a low estimate of 15.00.
Current 3.430
EPS
Actual
Estimate
-0.86-0.65-0.43-0.22
Institutional Holdings
Institutions: 214
Institutional Holdings: 67.85M
% Owned: 110.63%
Shares Outstanding: 61.33M
TypeInstitutionsShares
Increased
51
2.54M
New
25
3.18M
Decreased
48
3.83M
Sold Out
22
2.57M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.31%
Key Executives
Non-Executive Chairman/Independent Director
Paulo Costa
President/Chief Executive Officer/Director
Scott Koenig
Chief Financial Officer/Senior Vice President/Secretary
James Karrels
Chief Operating Officer
Eric Risser
Senior Vice President/Chief Scientific Officer
Ezio Bonvini
Senior Vice President
Stephen Eck
Senior Vice President
Thomas Spitznagel
Vice President/General Counsel
Jeffrey Peters
Vice President/Controller/Treasurer
Lynn Cilinski
Independent Director
Karen Ferrante
Independent Director
Edward Hurwitz
Independent Director
Scott Jackson
Independent Director
Federica O'Brien
Independent Director
Jay Siegel
Independent Director
David Stump
No Data
No Data
About MGNX
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company's lead product, MARGENZA, is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. In addition, the Company has a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, such as Flotetuzumab (CD123 x CD3), Retifanlimab (PD-1), Enoblituzumab (anti-B7-H3), Tebotelimab (PD-1 x LAG-3), MGD019 (PD-1 x CTLA-4), MGC018 (B7-H3), IMGC936 (ADAM9) and MGD014 (HIV x CD3). These pipelines are created primarily using its antibody-based technology platforms.
Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.